Advertisement

NanoEthics

, Volume 8, Issue 1, pp 19–28 | Cite as

The Clinical Research of Nanomedicine: A New Ethical Challenge?

  • Urban Wiesing
  • Jens ClausenEmail author
Original Paper

Abtract

Nanomedicine promises unprecedented innovations for diagnosis and therapy as well as for predicting and preventing diseases. On the other hand it raises fears linked to new and unknown characteristics of nanoscale materials. Both, promises and fears, are closely linked to the realm of uncertainty. To a large extent it is currently not known which expectations could become reality and which suspected adverse events might come true. Medicine is quite familiar with decision-making under uncertainty. Rules and regulations for clinical research have been developed to reduce possible harm for research participants without abandoning necessary investigations. Here we examine whether clinical research trials of nanomedicine need new regulations and conclude that the established rules should suffice.

Keywords

Research ethics Uncertainty Risk Precautionary principle 

References

  1. 1.
    Anonymous (2008) The same old story. Nat Nanotechnol 3:S. 697Google Scholar
  2. 2.
    Alexiou C (2013) Nanomedicine. innovative applications in medicine. HNO 61:197–201CrossRefGoogle Scholar
  3. 3.
    Allhoff F (2009) Risk, precaution, and emerging technologies. Stud Ethics Law Technol 3:1–27CrossRefGoogle Scholar
  4. 4.
    Allhoff F, Lin P, Moore D (2010) What is nanotechnoliogy and why does it matter? From science to ethics. Wiley-Blackwell, West SussexCrossRefGoogle Scholar
  5. 5.
    Arvizo RR, Bhattacharyya S, Kudgus RA, Giri K, Bhattacharya R, Mukherjee P (2012) Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev 41:2943–2970Google Scholar
  6. 6.
    Berger F, Gevers S, Siep L, Weltring K-M (2008) Ethical, legal and social aspects of brain-implants using nano-scale materials and techniques. Nanoethics 2:241–249CrossRefGoogle Scholar
  7. 7.
    Commission E (2006) Nanomedicine: naotechnology for health. european technology platform—strategic research agenda for nanomedicine. Office for Official Publications of the European Communities, LuxembourgGoogle Scholar
  8. 8.
    DeVille KA (2008) Law, regulation and the medical use of nanotechnology. In: Jotterand F (ed) Emerging conceptual, ethical and policy issues in bionanotechnology. Springer, Berlin, pp 181–200Google Scholar
  9. 9.
    Drexler E (1987) Engines of creation—the coming era of nanotechnology. Anchor, New YorkGoogle Scholar
  10. 10.
    Dresser R (2012) Building an ethical foundation for first-in-human nanotrials. J Law Med Ethics 40:802–808Google Scholar
  11. 11.
    Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8:2101–2141CrossRefGoogle Scholar
  12. 12.
    EGE (2007) Opinion 21 on the ethical aspects of nanomedicine. European Communities’ Publications Office, LuxembourgGoogle Scholar
  13. 13.
    Emanuel EJ, Wendler D, Grady C (2000) What makes clinical research ethical? JAMA 283:2701–2711CrossRefGoogle Scholar
  14. 14.
    Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J (2013) The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9:1–14CrossRefGoogle Scholar
  15. 15.
    Fatehi L, Wolf SM, McCullough J, Hall R, Lawrenz F, Kahn JP, Jones C, Campbell SA, Dresser RS, Erdman AG, Haynes CL, Hoerr RA, Hogle LF, Keane MA, Khushf G, King NM, Kokkoli E, Marchant G, Maynard AD, Philbert M, Ramachandran G, Siegel RA, Wickline S (2012) Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J Law Med Ethics 40:716–750Google Scholar
  16. 16.
    Gordijn B (2005) Nanoethics: from utopian dreams and apocalyptic nightmares towards a more balanced view. Sci Eng Ethics 11:521–533CrossRefGoogle Scholar
  17. 17.
    Grunwald A (2008) Auf dem Weg in eine nanotechnologische Zukunft: Philosophisch-ethische Fragen. Alber, FreiburgGoogle Scholar
  18. 18.
    Grunwald A (2012) Responsible nanobiotechnology: philosophy and ethics. Pan Stanford, SingaporeCrossRefGoogle Scholar
  19. 19.
    Hall RM, Sun T, Ferrari M (2012) A portrait of nanomedicine and its bioethical implications. J Law Med Ethics 40:763–779Google Scholar
  20. 20.
    Hansson SO (2006) Great uncertainty about small things. In: Schummer J, Baird D (eds) Nanotechnology challenges—implications for philosophy, ethics and society. World Scientific Publishing, Singapur, pp 315–325CrossRefGoogle Scholar
  21. 21.
    Hong Z, Zhang P, He C, Qiu X, Liu A, Chen L, Chen X, Jing X (2005) Nano-composite of poly(L-lactide) and surface grafted hydroxyapatite: mechanical properties and biocompatibility. Biomaterials 26:6296–6304CrossRefGoogle Scholar
  22. 22.
    Hunziker P (2013) Nanomedicine: the use of nano-scale science for the benefit of the patient. Basel, CLINAM—European Foundation for Clinical Nanomedicine www.clinam.org
  23. 23.
    Iancu C, Mocan L (2011) Advances in cancer therapy through the use of carbon nanotube-mediated targeted hyperthermia. Int J Nanomedicine 6:1675–1684CrossRefGoogle Scholar
  24. 24.
    Jömann N, Ach JS (2006) Ethical implications of nanobiotechnology—state-of-the-art survey of ethical issues related to nanobiotechnology. In: Ach JS, Siep L (eds) Nano-bio-ethics. ethical and social dimensions of nanobiotechnology. LIT, Berlin, pp 13–62Google Scholar
  25. 25.
    Juliano R (2013) Nanomedicine: is the wave cresting? Nat Rev Drug Discov 12:171–172CrossRefGoogle Scholar
  26. 26.
    Kermisch C (2012) Do new ethical issues arise at each stage of nanotechnological development? Nanoethics 6:29–37CrossRefGoogle Scholar
  27. 27.
    King NM (2012) Nanomedicine first-in-human research: challenges for informed consent. J Law Med Ethics 40:823–830Google Scholar
  28. 28.
    Mastroianni AC (2006) Liability regulation and policy in surgical innovation: the cutting edge of research and therapy. Health Matrix Cleve 16:351–442Google Scholar
  29. 29.
    Merkel R et al (2007) Intervening in the brain: changing psyche and society. Springer, BerlinGoogle Scholar
  30. 30.
    Müri W (1986) Der Arzt im Altertum. Griechische und lateinische Quellenstücke von Hippokrates bis Galen mit der Übertragung ins Deutsche. Wiss. Buchgesellschaft, DarmstadtGoogle Scholar
  31. 31.
    Nordmann A (2007) If and then: a critique of speculative nanoethics. Nanoethics 1:31–46CrossRefGoogle Scholar
  32. 32.
    Oberdörster G (2010) Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 267:89–105CrossRefGoogle Scholar
  33. 33.
    Resnik DB (2007) Beyond post-marketing research and MedWatch: long-term studies of drug risks. Drug Des Devel Ther 1:1–5Google Scholar
  34. 34.
    Resnik DB (2012) Responsible conduct in nanomedicine research: environmental concerns beyond the common rule. J Law Med Ethics 40:848–855Google Scholar
  35. 35.
    Resnik DB, Tinkle SS (2007) Ethical issues in clinical trials involving nanomedicine. Contemp Clin Trials 28:433–441CrossRefGoogle Scholar
  36. 36.
    Schermer M (2009) The mind and the machine. on conceptual and moral implications of brain-machine interaction. Nanoethics 3:217–230CrossRefGoogle Scholar
  37. 37.
    Siep L (2008) Ethical problems of nanobiotechnology. In: Ach JS, Lüttenberg B (eds) Nanobiotechnology. Nanomedicine and Human Enhancement. LIT, Berlin, pp 17–26Google Scholar
  38. 38.
    SRU (2011) Vorsorgestrategien für Nanomaterialien: Sondergutachten des Sachverständigenrats für UmweltfragenGoogle Scholar
  39. 39.
    Suyatin DB, Wallman L, Thelin J, Prinz CN, Jorntell H, Samuelson L, Montelius L, Schouenborg J (2013) Nanowire-based electrode for acute in vivo neural recordings in the brain. PLoS One 8:e56673CrossRefGoogle Scholar
  40. 40.
    Swierstra T, Rip A (2007) Nano-ethics as NEST-ethics: patterns of moral argumentation about new and emerging technology. Nanoethics 1:3–20CrossRefGoogle Scholar
  41. 41.
    Toellner R (1990) Problemgeschichte: Entstehung der Ethik-Kommissionen. In: Toellner R (ed) Die Ethik-Kommission in der Medizin: Problemgeschichte, Aufgabenstellung, Arbeitsweise, Rechtsstellung und Organisationsformen Medizinischer Ethik-Kommissionen. Gustav Fischer, Stuttgart, pp 3–18Google Scholar
  42. 42.
    Tran LA, Wilson LJ (2011) Nanomedicine: making controllable magnetic drug delivery possible for the treatment of breast cancer. Breast Cancer Res 13:303CrossRefGoogle Scholar
  43. 43.
    Wagner V et al (2006) The emerging nanomedicine landscape. Nat Biotechnol 24:1211–1217CrossRefGoogle Scholar
  44. 44.
    Wieland W (2004) Diagnose. Überlegungen zur Medizintheorie. Hoof, WarendorfGoogle Scholar
  45. 45.
    Wiesing U (1995) Kunst oder Wissenschaft? Konzeptionen der Medizin in der deutschen Romantik. Frommann-Holzboog, Stuttgart-Bad CannstattGoogle Scholar
  46. 46.
    Wolf SM (2012) Introduction: the challenge of nanomedicine human subjects research: protecting participants, workers, bystanders, and the environment. J Law Med Ethics 40:712–715Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.International Center for Ethics in Science and HumanitiesTübingenGermany
  2. 2.Werner Reichardt Center for Integrative Neuroscience (CIN)TübingenGermany
  3. 3.Institute for Ethics and History of MedicineTübingenGermany

Personalised recommendations